Scantox A/S

Beskrivelse af virksomhedens væsentligste aktiviteter

Scantox A/S (”Scantox”) was founded in 1977 and is a market- leading GLP (“Good Laboratory Practice”) accredited Contract Research Organization in Europe, providing pre-clinical research services, including regulatory in-vivo toxicology studies, that are critical to any drug development process. Scantox has a vital role in the Europe pharma and biotech community, where the company has established solid relationships and enjoys a broad and loyal customer base, leveraging its strong track-record and more than 40 years of scientific experience

Beskrivelse af udviklingen i virksomhedens aktiviteter og økonomiske forhold

In 2024, the Company's revenue amounted to DKK 146.8 million (2023: DKK 148.0 million). The income statement for 2024 shows a profit of DKK 9.6 million (2023: 17.3 million) for the year, and the balance sheet on 31 December 2024 shows equity of DKK 22.7 million (2023: 42.2 million). The revenue and profit are lower than expected due to a general slowdown in the preclinical outsourcing market.
Total Equtiy decreased to DKK 22,670. Despite the overall decline, we remain confident on the continued long-term growth, and we have in 2024 invested in increasing capacity – especially in the new facility that became operational early 2025. Investments in property, plant and equipment were DKK 50.8 million.
Management finds the financial result for 2024 slightly unsatisfactory but remains confident on the continued long-term growth in the business.

Omtale af betydningsfulde hændelser, som er indtruffet efter regnskabsårets afslutning

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.

Beskrivelse af virksomhedens forventede udvikling

The current macroeconomic environment is making the market situation and the outlook for 2025 more uncertain than normally. With the utilization of investments made we expect revenue and operating profit to be at the same level as the 2024 result.
Knowledge resources
It is essential for the Company's continued growth to attract and retain skilled labour expertise in,
among other things, technical know-how, which helps to develop new products adapted to customer
needs. To ensure development, the company invests in the necessary resources just as the employees
are offered to improve their skills in relevant course progra
Research and development activities
The Company continuously uses resources to develop their services, with constantly focus onanimal welware to keep the market leading profile.
Uncertainty relating to recognition and measurement
Revenue recognition
Scantox’s customer contracts are designed to allow the Group to perform specific studies, usually at a fixed price. Revenue is recognized with the production method using estimates of the value produced in the fiscal period. The revenue estimates inherently pose some measurement uncertainty, though they are subject to extensive control and assessment.